S
Silvio E. Inzucchi
Researcher at Yale University
Publications - 511
Citations - 64889
Silvio E. Inzucchi is an academic researcher from Yale University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 92, co-authored 424 publications receiving 54101 citations. Previous affiliations of Silvio E. Inzucchi include University of Toronto & American Diabetes Association.
Papers
More filters
Journal ArticleDOI
Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutations.
Journal ArticleDOI
Aspirin for primary prevention of cardiovascular events in people with diabetes: A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation: (Diabetes Care (2010) 33, (1395-1402))
Michael Pignone,Mark J. Alberts,John A. Colwell,Mary Cushman,Silvio E. Inzucchi,Debabrata Mukherjee,Robert S. Rosenson,Craig D. Williams,Peter W.F. Wilson,M. S. Kirkman +9 more
Journal Article
Adverse Cardiovascular Risk Factors Compared to Glycemic Control in Type 2 Diabetes (T2DM) Patients without Clinically Evident Coronary Artery Disease (CAD)
Journal ArticleDOI
Taking care of volunteers in a stroke trial: a new assisted-management strategy.
Amber Stuart,Jason J. Sico,Jason J. Sico,Catherine M. Viscoli,Ashis H Tayal,Ashis H Tayal,Silvio E. Inzucchi,Gary A. Ford,Karen L. Furie,Robert Côté,J. David Spence,David Tanne,Walter N. Kernan +12 more
TL;DR: A strategy of monitoring care and providing feedback was associated with high average yearly achievement of 3 priority secondary prevention goals, but the majority of trial participants did not persist in being at goal over time.
Journal ArticleDOI
Effect of treatment with dapagliflozin is consistent across the range of body mass index in patients with hfref: an analysis of the dapa-hf trial
Pardeep S. Jhund,Carly Adamson,Silvio E. Inzucchi,Mikhail Kosiborod,Anna Maria Langkilde,Felipe Martinez,Olof Bengtsson,Piotr Ponikowski,Marc S. Sabatine,Mikaela Sjoestrand,Scott D. Solomon,John J.V. McMurray +11 more
TL;DR: In DAPA-HF, dapagliflozin (10mg qd) vs. placebo reduced the risk of worsening HF and CV death, and whether their benefits vary depending on body-mass-index (BMI) has not been assessed in HFrEF.